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Despite declining incidence rates, gastric cancer (GC) is a major cause of death worldwide. Its aetiology may involve dietary antioxidant
micronutrients such as carotenoids and tocopherols. The objective of this study was to determine the association of plasma levels of
seven common carotenoids, their total plasma concentration, retinol and a-a n dg-tocopherol, with the risk of gastric adenocarcinoma in
a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort involving 10
countries. A secondary objective was to determine the association of total sum of carotenoids, retinol and a-tocopherol on GCs by
anatomical subsite (cardia/noncardia) and histological subtype (diffuse/intestinal). Analytes were measured by high-performance liquid
chromatography in prediagnostic plasma from 244 GC cases and 645 controls matched by age, gender, study centre and date of blood
donation. Conditional logistic regression models adjusted by body mass index, total energy intake, smoking and Helicobacter pylori
infection status were used to estimate relative cancer risks. After an average 3.2 years of follow-up, a negative association with GC risk
was observed in the highest vs the lowest quartiles of plasma b-cryptoxanthin (odds ratio (OR)¼0.53, 95% confidence intervals
(CI)¼0.30–0.94,Ptrend¼0.006), zeaxanthin (OR¼0.39, 95% CI¼0.22–0.69, Ptrend¼0.005), retinol (OR¼0.55, 95% CI¼0.33–0.93,
Ptrend¼0.005) and lipid-unadjusted a-tocopherol (OR¼0.59, 95% CI¼0.37–0.94, Ptrend¼0.022). For all analytes, no heterogeneity of
risk estimates or significant associations were observed by anatomical subsite. In the diffuse histological subtype, an inverse association was
observed with the highest vs lowest quartile of lipid-unadjusted a-tocopherol (OR¼0.26, 95% CI¼0.11–0.65, Ptrend¼0.003). These
results show that higher plasma concentrations of some carotenoids, retinol and a-tocopherol are associated with reduced risk of GC.
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yGastric cancer (GC) presents wide international variation in
incidence rates, with a general overall decline in the past several
decades (Kelley and Duggan, 2003). In Western countries, the
overall decline in GC incidence has been contrasted by a relative
increase in cardial GC rates (Botterweck et al, 2000a; Corley and
Kubo, 2004) and, from a histological point of view, the diffuse
subtype is becoming relatively more common (Lauren and
Nevalainen, 1993). GC risk factors may differ based on the
histological subtype, or the anatomical localisation of GCs within
the stomach (Correa and Shiao, 1994; Engel et al, 2003; Kelley and
Duggan, 2003).
The intake of some fruits and vegetables has been suggested to
be inversely associated with the risk of GCs (World Cancer
Research Fund, 1997; Riboli and Norat, 2003; Gonzalez et al, 2006),
an effect that may be owing to the various carotenoids and
antioxidant vitamins present in these foods (Donaldson, 2004).
Several case–control studies have shown strong inverse associa-
tions between GC risk and higher consumption of some of these
nutrients (Buiatti et al, 1990, 1991; Gonzalez et al, 1994; Hansson
et al, 1994; Ekstrom et al, 2000). Results from prospective dietary
studies are conflicting and show either a strong protection (Zheng
et al, 1995) or no clear inverse associations between the dietary
intake of carotenoids and GC risk (Ocke et al, 1995; Botterweck
et al, 2000b).
However, estimation of dietary carotenoid intakes is prone to
many measurement errors and may not reflect their actual
bioavailability, which can be better estimated by measures of
circulating blood carotenoid levels. Certain plasma carotenoids
can be considered as biomarkers of intake of fruits and vegetables
(Al Delaimy et al, 2005a,b). Some earlier studies in Western
populations (Willett et al, 1984; Stahelin et al, 1991) and more
recent ones in high-risk Chinese populations (Abnet et al, 2003;
Taylor et al, 2003; Yuan et al, 2004) show a higher GC risk in those
with lower blood levels of some carotenoids or retinol. In contrast,
some recent studies show a positive association between blood
a-tocopherol levels and risk of GCs of the stomach cardia (Nouraie
et al, 2005) and noncardial regions (Taylor et al, 2003) as well
as the progression of dysplastic lesions to GCs (You et al, 2000).
Only a few of the studies to date have been prospective in nature,
few have considered histological subtype or anatomical tumour
location and fewer still have accounted for Hp infection, a strong
potential confounding factor. Further, it is unclear whether any
observed association is conferred by individual carotenoids or is
owing to the combined effect of blood carotenoids. Thus, the aim
of this study was to determine the association of plasma levels
of seven common individual carotenoids, retinol and a- and
g-tocopherols as well as total blood carotenoid levels with risk of
GC, with consideration of Hp infection status, in a case–control
study nested within the European Prospective Investigation into
Cancer and Nutrition (EPIC-EURGAST). The effects of the total
sum of carotenoids as well as the effects of retinol and
a-tocopherol were further explored by anatomical subsite and
histological subtype. In addition, the association of dietary
b-carotene, retinol and vitamin E with GC risk was also assessed.
MATERIALS AND METHODS
Study population and collection of blood samples
The rationale and methods of the EPIC study have been previously
discussed in detail (Riboli and Kaaks, 1997; Riboli et al, 2002).
Briefly, the EPIC cohort consists of 23 centres in 10 European
countries (Denmark, France, Greece, Germany, Italy, Netherlands,
Norway, Spain, Sweden and United Kingdom). Between 1992 and
1998, country-specific dietary questionnaires, standardised life-
style and personal history questionnaires, anthropometric data
and blood samples were collected. Values for total energy intake
and dietary b-carotene (the only dietary carotenoid currently
available in the EPIC dietary database), retinol and vitamin E
(includes a- and g-tocopherols along with other tocopherols and
tocotrienols) were computed using country-specific food composi-
tion tables.
In each of the 23 recruitment centres, blood samples of at least
30ml were drawn from all participants and stored at 5–101C
protected from light and transported to local laboratories for
processing and aliquoting (Riboli and Kaaks, 1997; Riboli et al,
2002). The only exceptions were the EPIC-Oxford centre (UK),
where blood samples were collected from a network of general
practitioners and transported to a central laboratory by post and
centres in Sweden and Denmark where blood was aliquoted within
1h of drawing. Previous studies have shown that carotenoids are
not appreciably affected by short-term storage and transport
(Hankinson et al, 1989; Key et al, 1996).
In all countries, except Denmark and Sweden, blood was
separated into 0.5ml fractions (serum, plasma, red cells and buffy
coat for DNA extraction). Each fraction was placed into straws,
which were heat-sealed and stored ( 1961C) under liquid nitrogen.
In Denmark, blood fraction aliquots of 1.0ml were stored locally in
Nunc tubes at  1501C under nitrogen vapour. In Sweden, samples
were stored in  801C freezers.
Follow-up for cancer incidence and vital status
In EPIC, follow-up is based on population cancer registries
(Denmark, Italy, Netherlands, Norway, Spain, Sweden and the
United Kingdom) and other methods, such as health insurance
records, pathology registries and active contact of study subjects or
next of kin (France, Germany and Greece). The follow-up period
for the present study was for data reports received to the end of
October 2002, representing complete follow-ups until either
December 2000 or December 2001 for all centres using cancer
registry data and until 2002 for France, Germany and Greece.
Cancers of the stomach included cancers coded as C16 (10th
Revision of the International Statistical Classification of Diseases,
Injury and Causes of Death). The diagnosis, tumour site
classification and morphology (according to ICDO2 and Lauren
classifications) of each identified cancer was confirmed and
validated by an independent panel of pathologists with a
representative from each EPIC country and a coordinator using
original histological slides and/or re-cuts from the paraffin blocks
and histopathology reports.
Nested case–control study design and selection
of study subjects
Incident cases were study subjects who developed GC after
recruitment into EPIC. The present study includes a total of
228 gastric adenocarcinomas and 16 adenocarcinomas of the
gastro-oesophageal junction (GEJ), which are grouped together
(n matched controls¼645) and referred to as GC. GC were divided
into the following three groups by anatomical subsite: (i) tumours
originating from the gastric cardia (n cases¼70, n matched
controls¼176), combining tumours that reached the GEJ, either
crossing it or from below (all 16 GEJ cancers) or not, (ii)
noncardial tumours (n cases¼127, n matched controls¼344)
grouping cases from other sites in the stomach and (iii) tumours
from unknown or mixed sites (n cases¼47, n matched
controls¼125). When divided by histological subtype, of the 244
GC cases, 93 (n matched controls¼244) were classified as diffuse,
and 96 (nmatched controls¼256) as intestinal according to the
Lauren classification. The remainder (n cases¼55, n matched
controls¼145) were of unknown or mixed histological types. All
gastric lymphomas, gastric stump cancers, other gastric nonadeno-
carcinoma and otherwise unspecified cancers of the stomach were
excluded from this analysis. For each identified cancer case,
control subjects with available blood samples were randomly
Plasma carotenoids and gastric cancer risk in EPIC
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(except nonmelanoma skin cancer) at the time of diagnosis of the
case patient. Controls were matched by gender, age group (72.5
years), study centre and date of blood sample collection (745
days). The study was conducted in two phases. The target case to
control matching ratio was 1:4 for the first phase (88 GC cases)
and 1:2 for the second phase (156 GC cases). This study was
approved by the Ethical Review Board of the International Agency
for Research on Cancer (IARC, Lyon, France) and those of all
individual EPIC centres.
Laboratory assay – Helicobacter pylori infection status
The methodology for the determination of Hp infection status is
detailed elsewhere (Gonzalez et al, 2006; Palli et al, 2006). Briefly,
quantification of anti-Hp antibodies in plasma of all cases
and controls was performed by ELISA using the lysate of the Hp
CCUG strain. Various dilutions of plasma samples (starting
dilution 1:200) were incubated with the Hp lysate in solid phase
(1mgml
 1). After 1h and extensive washings, plates were
incubated with an alkaline phosphatase-conjugated polyclonal
affinity-purified goat anti-human IgG (Sigma chemical Co., St
Louis, MO, USA). After 3h incubation and further washings, the
enzymatic reaction was revealed by the addition of p-nitro-
phenylphosphate as a substrate. Hp-specific IgG antibody titres
were expressed as ELISA Units (EU), and were determined by
interpolation relative to a standard curve constructed by a serial
dilution of a standard positive control. A cutoff value of 100EU
was defined using serum samples from individuals negative
for H. pylori infection as determined by clinical, microbiological
and serological assays. Serum samples with EU values above
100 were considered as positive for anti-H. pylori IgG antibodies.
In previous experiments, this assay exhibited specificity and
sensitivity higher than 90%.
Laboratory assay – analytes
All analyses were performed at IARC. Plasma samples were
analysed for seven carotenoids (a-carotene, b-carotene, b-crypto-
xanthin, canthaxanthin, lutein, lycopene and zeaxanthin), as well
as retinol, a-tocopherol and g-tocopherol using a reverse-phase
high-performance liquid chromatography method (HPLC) (Ste-
ghens et al, 1997) on an HPLC-1100 system (Hewlett Packard,
Wilmington, IL, USA) with a C18-Adsorbosphere column (Alltech,
Deerfield, IL, USA). Plasma samples (200ml) were thawed and
deproteinated with alcohol, extracted with hexane, dried under
vacuum and then reconstituted with 300ml of a mixture of
methanol (88%)/ethanol (10%)/hexane (2%). In order to correct
for recoveries, internal standards (Tocol for the tocopherols;
Echinenone for the carotenoids) were run with each sample. In
each batch, an external calibration was also performed using the
standard solutions at eight different concentrations. Peaks for
carotenoids that were under the detection limits were set to zero,
whereas peaks that could not be detected because of technical
problems were excluded from the study. The detection limits were
set at: 0.062mgdl
 1 for a-carotene, b-carotene and b-crypto-
xanthin, 0.060mgdl
 1 for canthaxanthin, 0.042mgdl
 1 for lutein
and zeaxanthin, 0.078mgdl
 1 for lycopene, 0.074mgdl
 1 for retinol
and 1.898mgdl
 1 for the tocopherols. The coefficients of variation
were: 10.1% for a-carotene, 5.5% for b-carotene, 6.5% for
b-cryptoxanthin, 13.6% for canthaxanthin, 4.3% for lutein, 7.4%
for retinol, 7.4% for lycopene, 8.4% for zeaxanthin, 5.6% for
a-tocopherol and 8.4% for a-tocopherol. No significant between-
day drift was observed.
As different carotenoids tend to be, for the most part, present
together in various food sources, and as carotenoids may act
cumulatively together (Liu, 2004), it was decided to create a
variable representing the total sum of the concentration of the
seven individual carotenoids analysed, expressed in terms of both
weight (mgdl
 1) and molar equivalents (mmoll
 1). The methodo-
logy used in the present study allows the separation of lutein and
zeaxanthin. As many publications in this field do not separate
these analytes, the sum of the concentrations of lutein and
zeaxanthin was also calculated for comparison purposes.
In addition, the composition of 22 individual saturated and
unsaturated fatty acids was determined in plasma phospholipids
by gas chromatography using the method of Chajes et al (1999).
For all analytes, matched case–control sets were assayed in the
same batch in order to minimise errors from batch to batch
variations. Two quality control samples were run per analysis
batch. Laboratory technicians were blinded to the case/control
status of all samples.
Statistical methods
Differences between cases and controls in mean levels for each
analyte were tested by paired t-tests of the log-transformed value
in each case–control set. In addition, Spearman’s correlations,
adjusted for age, body mass index, total energy intake, smoking
status/duration/intensity and Hp positivity, were calculated for the
matrix of log-transformed analytes, as well as for the correlation
of plasma and dietary b-carotene, retinol and vitamin E and the
correlation of plasma a- and g-tocopherols with total plasma fatty
acids and total plasma saturated fatty acids.
Odds ratios (OR) and 95% confidence intervals (95% CI) for GC
risk in relation to plasma analyte concentrations and for dietary
intake levels of dietary b-carotene, retinol and vitamin E were
calculated by conditional logistic regression (SAS statistical
software, version 9, SAS Institute, Cary, NC, USA), stratified by
the case–control set. The effects of potential confounders, other
than matching criteria, which are controlled for by design,
were examined by including additional regression terms into the
logistic regression models. Potential confounders included total
energy intake (in quartiles), body mass index (quartiles), Hp
infection status (yes/no) and duration/status/intensity of smoking
(variable categories: never-smokers, ex-smokers who smoked for
o10 years, ex-smokers who smoked for X10 years, smokers
who smoke o15cigarettesday
 1, smokers who smoke between
15–25cigarettesday
 1, smokers who smoke X25cigarettesday
 1
and missing). The effects of age, alcohol intake and the level of
schooling (an indicator variable for socioeconomic status) were
also examined, but they did not substantially alter the risk
estimates and were therefore not included in the final model. The
plasma analyte concentrations were examined by quartile cate-
gories with cut-points based on the distribution of each specific
analyte in the control subjects. For comparison purposes, models
for plasma tocopherols were also further adjusted for either plasma
total fatty acids or plasma total saturated fatty acids. Results for
a-tocopherol without an adjustment for plasma fatty acids are
referred to here as being ‘lipid-unadjusted’.
Models similar to the above were run with analytes included in
the model as non-log-transformed continuous variables with the
relative risk and 95% CI calculated as the risk for a change in the
plasma level by 1s.d. of the mean of all GC control subjects. A
similar approach was used for models analysing the dietary
variables. For all models, linear trend tests were determined using
a score variable with values from 1 to 4, consistent with the
quartile grouping.
All of the above models were also run for the total sum of
carotenoids, retinol and a-tocopherol by GC anatomical subsite
(cardia/noncardia) and histological subtype (diffuse/intestinal).
For comparability, the same quartile cut-points used for analysis
of all GCs were used in subgroup analyses. As described above, for
a number of reasons, some GC cases could not be classified by
anatomical subsite or histological subtype. For comparison
purposes, ORs were also calculated for these cases and matched
Plasma carotenoids and gastric cancer risk in EPIC
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variables, tests for heterogeneity were performed for comparisons
of GCs by subsite and by histological subtype (Rothman and
Greenland, 1998).
For all analytes, potential effect modification by gender, Hp
infection status and the time to diagnosis of GC of less than 2 years
or more than 2 years was tested using the likelihood ratio test to
assess the statistical significance of a linear interaction. For the
assessment of interaction for time to diagnosis of GC, each control
set was assigned the value for years of follow-up of its matched
case. No overall significant interactions were observed for any of
these variables. However, Hp infection status was nonetheless
placed in the model as a confounding variable because of its
potential to alter the systemic bioavailability of antioxidants and
affect their concentrations in gastric juice (Zhang et al, 2000;
Woodward et al, 2001; Annibale et al, 2002). In addition, to further
explore the role of Hp infection status and smoking status (never,
former, current, with missing in a separate category), unmatched
case–control analyses stratified by these variables and with each
analyte modelled individually as a continuous variable, were
performed using unconditional logistic regression models adjusted
for matching variables, as well as the laboratory batch and all other
adjustment variables described above.
RESULTS
Baseline characteristics and description of the study
population
The mean age at recruitment of GC cases and controls was 59.1
years (Table 1). On average, GC cases had 3.2 years between blood
donation and the time of diagnosis and had a higher percentage of
Hp positivity than controls (Table 1). The data set included 137
male cases and 349 controls, and 107 female cases and 296 controls
(Table 1). Adjusted Spearman’s correlations among the analytes
were strongest between a- and b-carotene (r¼0.70, Po0.001), and
lutein and zeaxanthin (r¼0.76, Po0.001). Retinol was very weakly
correlated with individual carotenoids and with the sum of all
carotenoids (r¼0.19, Po0.001). The correlations between the
plasma and dietary values of b-carotene (r¼0.28, Po0.001) and
retinol (r¼0.20, Po0.001) were modest, whereas that of plasma a-
plus g-tocopherol with dietary vitamin E (includes tocopherols and
tocotrienols) was weak (r¼0.07, P¼0.05). Plasma a-tocopherol
was strongly correlated with both total plasma fatty acids (r¼0.46,
Po0.0001) and total plasma saturated fatty acids (r¼0.49,
Po0.001), whereas the correlations for plasma g-tocopherol were
weaker (r¼0.25, Po0.001; r¼0.31, Po0.001, respectively).
Gastric cancer
Table 2 shows the mean value and s.d. in GC cases and controls for
all analytes. The mean plasma concentrations of zeaxanthin and
retinol, but not any of the other analytes, were significantly lower
in cases than controls (Table 2). When considering quartiles of
individual analytes in plasma and GC risk, b-cryptoxanthin
(Ptrend¼0.006), zeaxanthin (Ptrend¼0.005), retinol (Ptrend¼0.005)
and lipid-unadjusted a-tocopherol (Ptrend¼0.022) showed signifi-
cant negative associations at the highest vs the lowest quartiles
(Table 3). The results of the effects of the other analytes were not
statistically significant (Table 3). When the plasma levels of
individual carotenoids were summed (mgdl
 1), the total variable
showed a nonstatistically significant negative association with GC
Table 1 Baseline characteristics and description of the study population of cases and controls in GCs
Gastric cancer
Cases (n¼244) Controls (n¼645)
Age at recruitment
a 59.1 (43.3–71.2) 59.1 (42.8–72.1)
Age at diagnosis
a 62.4 (44.6–74.1) —
Mean number of years between blood donation and diagnosis
a 3.2 (0.4–7.2) —
No. and (%) of Hp-positive subjects 203 (83.2) 432 (67.0)
No. and (%) of Hp-negative subjects 41 (16.8) 213 (33.0)
Body mass index
a 26.2 (20.5–32.6) 26.7 (20.9–34.2)
No. and (%) of male subjects 137 (56.1) 349 (54.1)
No. and (%) of female subjects 107 (43.9) 296 (45.9)
Smoking status/duration/intensity
No. and (%) of never smokers 81 (33.2) 289 (44.8)
No. and (%) of ex-smokers, duration of smoking o10 years 10 (4.1) 28 (4.3)
No. and (%) of ex-smokers, duration of smoking X10 years 71 (29.1) 176 (27.3)
No. and (%) of ex-smokers, missing duration of smoking 5 (2.0) 10 (1.6)
No. and (%) of smokers, o15cigarettesday
 1 28 (11.5) 58 (9.0)
No. and (%) of smokers, X15 to o25cigarettesday
 1 29 (11.9) 43 (6.7)
No. and (%) of smokers, X25cigarettesday
 1 11 (4.5) 13 (2.0)
No. and (%) with missing smoking status 9 (3.7) 28 (4.3)
Grouping by anatomical subsite
Cardial, no. and (%) of subjects 70 (28.7) 176 (27.3)
Noncardial, no. and (%) of subjects 127 (52.0) 344 (53.4)
Unknown or mixed subsite, no. and (%) of subjects 47 (19.3) 125 (19.4)
Grouping by histological subtype
Diffuse, no. and (%) of subjects 93 (38.1) 244 (37.8)
Intestinal, no. and (%) of subjects 96 (39.4) 256 (39.7)
Unknown or mixed subtype, no. and (%) of subjects 55 (22.5) 145 (22.5)
GC, gastric cancer.
aValues are means (5th–95th percentile range). Distribution of cases/controls by EPIC country: Denmark¼23/39; France¼3/10; Germany¼30/87;
Greece¼12/26; Italy¼44/147; Netherlands¼19/60; Spain¼28/85; Sweden¼57/112 and United Kingdom¼28/79.
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Plasma levels (lgdl
 1)
GC cases (n¼244) GC controls (n¼645)
Analyte
Geometric
mean Median
5th–95th
percentile
Geometric
mean Median
5th–95th
percentile P-mean diff
a
a-Carotene 6.7 5.3 1.5–22.4 6.6 5.4 1.4–19.6 0.72
b-Carotene 19.0 17.7 5.6–53.6 19.0 17.8 5.5–52.8 0.51
b-Cryptoxanthin 9.6 8.1 2.0–38.3 11.9 10.7 2.6–40.9 0.01
Canthaxanthin 1.9 0.7 0.1–4.5 2.0 0.8 0.2–4.5 0.98
Lutein 20.2 19.2 8.9–46.0 21.4 20.0 9.0–48.8 0.63
Lycopene 26.0 27.2 7.8–70.7 28.6 29.2 8.0–72.6 0.18
Zeaxanthin 4.9 4.0 1.3–9.1 5.7 4.7 1.7–10.8 o0.01
Total sum of carotenoids 91.5 92.8 40.4–208.4 98.2 98.7 41.8–204.2 0.14
Retinol 49.0 48.2 33.8–70.0 50.5 50.1 33.5–71.5 0.01
a-Tocopherol 1156.2 1131.4 809.3–1696.3 1186.1 1181.2 789.4–1748.1 0.08
g-Tocopherol 80.4 81.4 31.7–219.9 80.5 80.7 32.6–196.1 0.78
GC, gastric cancer; s.d., standard deviation.
aTwo-sided P-values of paired t-test on log-transformed values given for a difference in means between cases and controls per analyte.
For the sum of lutein/zeaxanthin, the mean concentration was 24.2mgdl
 1 in cases and 26.2mgdl
 1 in controls, with a P-value for difference of 0.16.
Table 3 OR for plasma levels of carotenoids, retinol and tocopherols and risk of GCs
OR for quartiles of plasma analyte levels
a category cut-points (lgdl
 1)
Analyte Ref. 2 3 4
P-value
for trend
b
OR of one 1s.d.
increase in plasma levels
c
a-Carotene o3.2 X3.2 to o5.4 X5.4 to o9.0 X9.0 8.2mgdl
 1
1.00 1.15 (0.72–1.83) 1.20 (0.72–1.83) 1.19 (0.71–1.99) 0.504 1.07 (0.94–1.22)
b-Carotene o12.0 Z12.0 to o17.8 X17.8 to o26.5 X26.5 18.9mgdl
 1
1.00 0.96 (0.60–1.79) 1.09 (0.67–1.79) 1.13 (0.69–1.86) 0.539 1.09 (0.94–1.27)
b-Cryptoxanthin o5.8 X5.8 to o10.7 X10.7 to o18.7 X18.7 13.5mgdl
 1
1.00 0.95 (0.61–1.46) 0.56 (0.35–0.90) 0.53 (0.30–0.94) 0.006 0.81 (0.65–1.00)
Canthaxanthin o0.4 X0.4 to o0.8 X0.8 to o1.6 X1.6 1.6mgdl
 1
1.00 0.97 (0.61–1.54) 1.04 (0.64–1.71) 0.80 (0.44–1.45) 0.630 1.08 (0.84–1.38)
Lutein o14.6 X14.6 to o20.0 X20.0 to o28.9 X28.9 13.3mgdl
 1
1.00 1.10 (0.69–1.74) 0.95 (0.57–1.56) 0.73 (0.43–1.37) 0.356 0.93 (0.75–1.15)
Lycopene o17.8 X17.8 to o29.2 X29.2 to o44.7 X44.8 20.6mgdl
 1
1.00 0.89 (0.56–1.40) 0.86 (0.55–1.36) 0.63 (0.36–1.09) 0.132 0.85 (0.69–1.04)
Zeaxanthin o3.2 X3.2 to o4.7 X4.7 to o6.7 X6.7 3.0mgdl
 1
1.00 0.62 (0.39–0.99) 0.68 (0.42–1.10) 0.39 (0.22–0.70) 0.005 0.65 (0.51–0.81)
Total sum of carotenoids o70.5 X70.5 to o98.7 X98.7 to o135.9 X135.9 50.3mgdl
 1
1.00 0.99 (0.62–1.59) 0.99 (0.61–1.59) 0.69 (0.39–1.21) 0.259 0.93 (0.76–1.13)
Retinol o42.4 X42.4 to o55.9 X55.9 to o63.8 X63.8 12.5mgdl
 1
1.00 0.99 (0.66–1.54) 0.55 (0.34–0.91) 0.55 (0.33–0.93) 0.005 0.80 (0.67–0.97)
a-Tocopherol
d o1022.0 X1022.0 to o1181.2 X1181.2 to o393.7 X1393.7 303.2mgdl
 1
1.00 0.62 (0.40–0.96) 0.61 (0.39–0.96) 0.59 (0.37–0.94) 0.022 0.90 (0.76–1.07)
g-Tocopherol
e o52.7 X52.7 to o80.7 X80.7 to o116.7 X116.7 50.3mgdl
 1
1.00 1.13 (0.69–1.87) 1.16 (0.68–1.99) 1.00 (0.56–1.78) 0.968 1.09 (0.90–1.31)
GC, gastric cancer; OR, odds ratios.
aValues are ORs (95% CI) derived from models based on quartiles of plasma levels of each analyte, adjusted for body mass index, total energy
intake, smoking status/duration/intensity and Hp status.
bP of w
2 test for trend using a continuous variable with 1df.
cValues are ORs (95% CI), derived from models as described
above, for a risk associated with an increase in plasma carotenoid level equivalent to 1s.d. of the mean level of the specific analyte in the controls, as specified in the table for each
analyte.
dResults for a-tocopherol adjusted by total plasma fatty acids: Q2¼0.54 (0.34–0.86); Q3¼0.52 (0.32–0.86); Q4¼0.48 (0.28–0.84); Ptrend¼0.009.
eResults for
g-tocopherol adjusted by total plasma fatty acids: Q2¼1.13 (0.68–1.87); Q3¼1.13 (0.65–1.95); Q4¼1.00 (0.55–1.82); Ptrend¼0.959.
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Ptrend¼0.259) (Table 3). Calculation of the total sum of
carotenoids based on molar equivalents of each carotenoid did
not change the GC risk association (highest vs lowest quartiles
OR¼0.71, 95% CI¼0.41–1.75, Ptrend¼0.314, OR for 0.92mmoll
 1
increase in plasma levels¼0.93, 95% CI¼0.77–1.14).
No significant association with GC risk was observed for the
sum of lutein/zeaxanthin. For this variable, the OR (95% CI) for
each quartile vs the lowest were as follows: Q2, 0.97 (0.61–1.54);
Q3, 0.86 (0.53–1.42) and Q4, 0.71 (0.40–1.25), with Ptrend¼0.229
(data not shown in Table 3). None of the risk estimates were
changed by exclusion of the 22 cases and 38 controls who had
developed a cancer at a site other than the stomach before
enrolment in the cohort.
Adjustment of a-o rg-tocopherol measures by plasma total fatty
acids (Table 3, footnotes) or total saturated fatty acids (data not
shown) did not materially change any of the GC risk estimates
obtained. Furthermore, in the above subset, comparisons of
unconditional logistic regression models (n cases¼43, n con-
trols¼121) adjusted by blood total cholesterol vs plasma total fatty
acids or total saturated fatty acids showed no differences in the GC
risk associations obtained (data not shown).
H. pylori infection status and smoking status For individual
carotenoids, no statistically significant effects or differences in
direction/magnitude of the effect were observed by Hp infection
status. For the total sum of carotenoids, the results for a
50.3mgdl
 1 unit increase (equivalent to the s.d. of the mean of
all GC controls) were as follows: (OR (95% CI)) Hp negative: 0.94
(0.60–1.49); Hp positive: 0.90 (0.73–1.12). For retinol, the ORs
for a 12.5mgdl
 1 unit increase in plasma levels were as follows:
Hp negative: 1.00 (0.66–1.53); Hp positive: 0.73 (0.60–0.90). For
a-tocopherol, the ORs for a 303.2mgdl
 1 unit increase in plasma
levels were: Hp negative: 1.13 (0.76–1.66), Hp positive: 0.82 (0.67–
1.00). A similar approach was used to explore any role of smoking
status, but no differences were observed for any of the analytes.
There was no significant interaction with GC risk between smoking
status and any of the analytes, including the carotenes.
Dietary values There were no significant differences between
cases and controls in the daily intake of b-carotene (mean7s.e.)
(cases: 2.9770.15, controls: 2.9270.10mgday
 1), retinol (cases:
1.0770.07, controls: 0.9270.04mgday
 1) and vitamin E (cases:
10.0070.33, controls: 10.2670.20mgday
 1). No significant GC
risk associations were observed for dietary b-carotene (OR of 1s.d.
increase in intake of 2.4mgday
 1¼1.04, 95% CI¼0.88–1.24,
Ptrend¼0.090), retinol (OR of 1s.d. increase in intake of
0.89mgday
 1¼1.10, 95% CI¼0.93–1.29, Ptrend¼0.450) and
vitamin E (OR of 1s.d. increase in intake of 5.10mgday
 1¼0.99,
95% CI¼0.81–1.22, Ptrend¼0.290). Tests for heterogeneity
between anatomical subsites for these dietary variables were not
statistically significant (b-carotene: P¼0.61; retinol: P¼0.59;
vitamin E: P¼0.23). Similarly, for grouping by the two histological
subtypes, the P-values for heterogeneity tests were as follows:
b-carotene: P¼0.39; retinol: P¼0.42 and vitamin E: P¼0.40. As a
result, analyses stratifying for subsite and subtype for the dietary
variables were not performed.
Grouping of GC by anatomical subsites
When explored by cardia or noncardia subsites, there was no
evidence that the association between the individual analytes and
risk was different. For b-cryptoxanthin and zeaxanthin, the two
individual carotenoids that exhibited the strongest association
with GC risk, the P-values for tests of heterogeneity between the
two subsites were 0.154 and 0.258, respectively. However, given the
potential of GC aetiology to differ by anatomical subsite, subgroup
analyses were performed for total sum of carotenoids (test for
heterogeneity P¼0.33), retinol (test for heterogeneity P¼0.44)
and a-tocopherol (test for heterogeneity P¼0.84). No significant
negative associations were observed for any of these variables in
the cardial or noncardial subsites (Table 4).
For comparison purposes, ORs for groups of cases (n¼47, n
matched controls¼125) of unknown or mixed anatomical subsites
were also calculated for each of the above analytes modelled as
continuous variables with a risk estimate for a unit increase
equivalent to the s.d. of the mean value of the analyte in all GC
controls: (i) for total sum of carotenoids, the OR (95% CI) for a
unit increase of 50.3mgdl
 1 was 0.84 (0.52–1.38), (ii) for retinol,
the OR for a unit increase of 12.5mgdl
 1 was 0.37 (0.19–0.71) and
(iii) for a-tocopherol, the OR for a unit increase of 303.2mgdl
 1
was 0.58 (0.36–0.93).
Grouping of GC by histological subtypes
When explored by diffuse and intestinal histological subtypes,
there was no evidence that the association with risk in the two
subtypes was different for individual carotenoids. Neither the
total sum of carotenoids (P heterogeneity¼0.19) nor retinol
(P heterogeneity¼0.10) showed any significant associations with
GC risk in either the diffuse or intestinal subtypes (Table 4).
However, a-tocopherol (P heterogeneity¼0.02) showed a signifi-
cant inverse association with the diffuse subtype at the highest
quartile of plasma concentrations vs the lowest (OR¼0.26, 95%
CI¼0.11–0.65, Ptrend¼0.003) (Table 4).
For comparison purposes, ORs for groups of cases (n¼55, n
matched controls¼145) of unknown or mixed histological
subtypes were also calculated for each of the above analytes,
modelled as continuous variables with a risk estimate for a unit
increase equivalent to the s.d. of the mean value of the analyte in
all GC controls: (i) for total sum of carotenoids, the OR (95% CI)
for a unit increase of 50.3mgdl
 1 was 0.86 (0.57–1.29), (ii) for
retinol, the OR for a unit increase of 12.5mgdl
 1 was 0.52 (0.32–
0.86) and (iii) for a-tocopherol, the OR for a unit increase of
303.2mgdl
 1 was 0.92 (0.67–1.25).
DISCUSSION
The results of this large, nested case–control study show that
higher plasma concentrations of some individual carotenoids
(b-cryptoxanthin, zeaxanthin), retinol and a-tocopherol are
associated with a significant lower risk of developing GC during
the follow-up period.
Carotenoids and tocopherols have been suggested to be cancer
preventive mainly because of their antioxidant properties, which
may lead to a reduction in the extent of oxidative stress, lipid
peroxidation and DNA damage, whereas retinol, along with the
provitamin A carotenoids, is involved in the control of cellular
growth kinetics (Sporn and Roberts, 1983). Despite this potential,
results from previous reports on dietary intake of carotenoids
assessed from dietary questionnaires have been mixed and many
have not shown strong associations with GC risk (Chyou et al, 1990;
Zheng et al, 1995; Botterweck et al, 2000b). To date, only a few
studies have considered prediagnostic blood levels of carotenoids
in association with GC risk. A small Japanese study found no
association between GC risk and blood levels of retinol, b-carotene
or a-tocopherol, but did not consider anatomical subsite or
histological subtype (Nomura et al, 1995). Larger studies, set in
high-risk Chinese populations, show either (i) a borderline
significant negative association between retinol and GCs of the
cardia, and between b-cryptoxanthin and noncardial GC, and
an increased risk of noncardial GC with higher levels of lutein/
zeaxanthin (Abnet et al, 2003) or (ii) an inverse effect of a- and
b-carotene and lycopene on GC risk, but without consideration of
anatomical subsite or histological subtypes (Yuan et al, 2004).
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focused on b-carotene (Correa et al, 1998). This study did not
observe any association with plasma levels of a-o rb-carotene and
GC risk, whereas previous prospective studies have shown lower
plasma levels of b-carotene in GC cancer cases vs controls in a
Western population (Eichholzer et al, 1996) and either an inverse
association (Yuan et al, 2004), no association (Abnet et al, 2003) or
a positive association (You et al, 2000) with GC risk in high-risk
Chinese populations. Intervention studies with b-carotene, how-
ever, have shown no effect on GC risk in low-risk populations
(Hennekens et al, 1996), and either no effect (Varis et al, 1998) or
mild protective effects in high-risk populations (Blot et al, 1995;
Correa et al, 2000). In the present study, no GC risk associations
were observed for dietary b-carotene and in a concurrent study
of fruit and vegetable intake based on the entire EPIC cohort, no
GC risk association was observed with the intake of fruiting and
root vegetables (Gonzalez et al, 2006), which are good sources
of carotenes (Al Delaimy et al, 2005a). Taken together, these
observations suggest that any protective effects of the carotenes, or
carotenoids in general, are likely to be small.
The present study did not observe any statistically significant
inverse associations with blood levels of lycopene, which is
obtained predominantly from tomatoes and tomato-based pro-
ducts. Blood lycopene levels have previously been shown to be
associated with an inverse GC risk (Yuan et al, 2004), but this was
in a high-risk Chinese population with low baseline lycopene
levels. It may be that, given the higher tomato consumption in
Western populations, both cases and controls in the present study
were above a threshold of lycopene effect levels.
Dietary lutein, zeaxanthin and b-cryptoxanthin, which belong to
the xanthophyll family of carotenoids and are found mostly in
corn, leafy green vegetables and citrus fruits, have been shown to
have no association with GC risk in ecological (Tsubono et al,
1999), case–control (Garcia-Closas et al, 1999; Chen et al, 2002)
and cohort (Botterweck et al, 2000b) studies. In a concurrent study
of fruit and vegetable intake based on the entire EPIC cohort,
a negative GC risk association was observed with the intake of
citrus fruits, some members of which are good sources of these
carotenoids (Gonzalez et al, 2006). Only two studies to date, both
in high-risk Chinese populations, have considered prediagnostic
blood levels of these carotenoids. One (Yuan et al, 2004) found no
risk association, whereas the other (Abnet et al, 2003) showed a
significant increased risk of noncardial GC with high intake of
lutein and zeaxanthin.
In general, retinol, which is mostly derived from animal sources,
has not previously been associated with GC risk in a prospective
setting (Abnet et al, 2003; Yuan et al, 2004; Nouraie et al, 2005).
However, in the present study, higher plasma retinol was
associated with a lower risk of GC. Its potential involvement in
important processes of carcinogenesis, namely cell differentiation,
adhesion and membrane permeability (van Poppel and van den
Berg, 1997), imply that it may have a role in cancer prevention.
Although these observations are encouraging, they require further
confirmation and validation.
Previous results from prospective studies analysing blood a-
tocopherol levels are conflicting, probably because they are
reflective of differences in the various populations analysed. For
example, in different high-risk Chinese populations, higher blood
a-tocopherol has been shown to have either a nonstatistically
significant (Yuan et al, 2004) or borderline significant (You et al,
2000) positive association with GC risk, or to be associated with a
marginal decreased risk of cardial GC and an increased risk of
noncardial GC (Taylor et al, 2003). Conversely, in a Finnish
population of smokers, higher baseline blood a-tocopherol
has been associated with a marginally significant increase in
the risk of cardial GC (Nouraie et al, 2005). In the present study,
higher plasma a-tocopherol level was negatively associated with
GC risk.
Table 4 OR for plasma levels of total sum of carotenoids, retinol and a-tocopherol and the risk of GCs by anatomical subsite and histological subtype
OR for quartiles of plasma levels
a
Analytes Ref. 2 3 4 P-value for trend
b OR of 1s.d. increase in plasma levels
c
Anatomical subsite
Cardial gastric cancers
n cases¼70, n controls¼176
Total sum of carotenoids 1.00 0.67 (0.29–1.56) 0.67 (0.26–1.45) 0.31 (0.08–1.16) 0.076 0.77 (0.49–1.21)
Retinol 1.00 1.10 (0.44–2.73) 0.31 (0.11–0.86) 0.56 (0.21–1.54) 0.089 0.88 (0.63–1.25)
a-Tocopherol 1.00 0.66 (0.28–1.55) 0.51 (0.21–1.24) 0.71 (0.29–1.75) 0.282 0.90 (0.64–1.26)
Noncardial gastric cancers
n cases¼127, n controls¼344
Total sum of carotenoids 1.00 1.22 (0.59–2.52) 1.70 (0.81–3.57) 0.85 (0.36–2.00) 0.955 1.03 (0.78–1.35)
Retinol 1.00 1.11 (0.57–2.14) 0.94 (0.46–1.91) 0.64 (0.30–1.37) 0.223 0.79 (0.59–1.04)
a Tocopherol 1.00 0.67 (0.35–1.27) 0.64 (0.34–1.22) 0.60 (0.29–1.24) 0.151 1.00 (0.78–1.29)
Histological subtype
Diffuse gastric cancers
n cases¼93, n controls¼244
Total sum of carotenoids 1.00 0.81 (0.33–1.97) 1.15 (0.49–2.67) 0.42 (0.15–1.17) 0.214 0.72 (0.50–1.04)
Retinol 1.00 0.70 (0.34–1.46) 0.31 (0.13–0.74) 0.66 (0.27–1.58) 0.081 0.75 (0.53–1.04)
a-Tocopherol 1.00 0.49 (0.22–1.12) 0.38 (0.16–0.88) 0.26 (0.11–0.65) 0.003 0.62 (0.44–0.88)
Intestinal gastric cancers
n cases¼96, n controls¼256
Total sum of carotenoids 1.00 0.66 (0.30–1.46) 0.70 (0.31–1.56) 0.66 (0.25–1.71) 0.397 0.98 (0.70–1.37)
Retinol 1.00 1.70 (0.79–3.67) 1.25 (0.53–2.93) 0.90 (0.37–2.16) 0.628 1.07 (0.78–1.46)
a Tocopherol 1.00 0.75 (0.35–1.59) 0.70 (0.34–1.47) 1.01 (0.47–2.20) 0.868 1.06 (0.79–1.44)
GC, gastric cancer; OR, odds ratios.
aValues are ORs derived from models described above based on quartiles of plasma levels of each analyte. Analyte specific quartile cut-points
are as listed on Table 3.
bP of w
2 test for trend using a continuous variable with 1df.
cValues are ORs (95% CI), derived from models as described above, for a risk associated with
an increase in plasma carotenoid level equivalent to 1s.d. of the mean level of the specific analyte in all GC controls (mgdl
 1): total carotenoids¼50.3; retinol¼12.5 and
tocopherol¼303.2.
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presented here are lipid-unadjusted. Some (Taylor et al, 2003;
Nouraie et al, 2005) but not all (You et al, 2000; Yuan et al, 2004) of
the above studies adjusted their blood tocopherol measures for
blood total cholesterol in order to correct for possible confound-
ing, as tocopherols are transported in the blood as part of
lipoprotein complexes (Willett, 1998). In the present study, this
adjustment was not possible as data on blood total cholesterol
values exist for only a subset of subjects. However, data on plasma
total fatty acids and total saturated fatty acids do exist for all
subjects. They may serve as surrogates for blood total cholesterol
because, in the subset of subjects described above, blood total
cholesterol was correlated with plasma total fatty acids (P¼0.46,
Po0.001) and total saturated fatty acids (P¼0.44, Po0.001),
whereas a-tocopherol was correlated with plasma total fatty acids
(P¼0.50, Po0.001), total saturated fatty acids (P¼0.48, Po0.001)
and blood total cholesterol (P¼0.50, Po0.001), which is in line
with previous observations (Willett et al, 1983). Adjustments of
plasma tocopherol measures for plasma total fatty acids or total
saturated fatty acids did not materially alter the GC risk estimates
obtained.
In the present study, no GC risk associations were observed for
increasing dietary intakes of retinol and vitamin E, whereas their
plasma measures showed significant negative GC risk associations
in the highest quartiles. This observed difference in effect may
suggest inaccuracies in the measured dietary values, perhaps
owing to measurement errors in assessment of intake, errors in
food composition tables or the lack of information on intake
from dietary supplements. However, it is also true that measures
of dietary intake, no matter how accurate, do not reflect the
bioavailability of the nutrients from various foods, the level of
absorption from the digestive tract or individual metabolising
differences, which are key in determining blood concentrations of
these nutrients. These results highlight the importance of
measuring blood biomarkers of intake in addition to dietary
intake levels.
The key advantage of the present study, aside from its
prospective design, is its ability to differentiate GCs by anatomical
subsite and histological subtype according to classifications made
by a team of expert pathologists. Of the previous studies, all of
them case–control, that have considered GC pathology in relation
to dietary carotenoids, some have failed to detect any associations
or differences by subtype (Boeing et al, 1991; Buiatti et al, 1991),
whereas others have shown mixed results (Gonzalez et al, 1994;
Harrison et al, 1997; Ekstrom et al, 2000), suggesting that the
effects of carotenoids might be similar in both histological
subtypes. In the present study, none of the analytes, with the
possible exception of a-tocopherol, showed any significant effects
by anatomical subsite or histological subtype. As data from
previous prospective studies on the effect of these analytes on
groupings of subsite and subtype are scarce, and the present
findings are based on a small number of cases, confirmation with
better-powered studies is necessary.
One of the key limitations of the present study may be the
relatively short follow-up time. Cases identified within a short
period after the start of the study may have suffered from some
symptoms, leading to dietary changes and hence alterations in the
blood carotenoid levels. In order to assess this, interaction tests
were run to determine if an effect modification existed with follow-
up time less than or equal to 2 years vs more than 2 years – none
was found for any of the analytes. This may suggest that in this
study, cases diagnosed close to study entry were not different
from those diagnosed later. However, given the long-term nature
of GC development and the relatively short follow-up time, some
caution is necessary in the interpretation of the results of the
present study. Another shortfall of this study is that the variable
for total carotenoids was estimated as a simple sum of all
carotenoid concentrations and thus does not account for factors
such as differences in antioxidative activity or other similar factors
that may affect their relative effects.
H. pylori positivity is a major GC risk factor for both the diffuse
and intestinal histological subtypes (Parsonnet et al, 1991;
Hansson et al, 1993a,b) and may alter systemic carotenoid levels
or their secretion patterns into the gastric juice (Zhang et al, 2000;
Annibale et al, 2002). In this study, no effect modification by Hp
status at baseline was observed, either because there is no such
modification or owing to the fact that a large percentage of cases
and controls were Hp positive. Although the results, with the
possible exception of a-tocopherol, do not show a difference of
effect based on Hp infection status, better powered studies are
called for.
Gastric cancer is known to be one of the many tobacco-related
cancers (Gonzalez et al, 2003), which have collectively been shown
to be modified by dietary b-carotene intake and smoking status
(Touvier et al, 2005). However, in the present study, no interaction
with GC risk was observed between smoking status and any of the
analytes, including b-carotene.
In summary, these results from the EPIC study show that plasma
levels of some individual carotenoids, retinol and a-tocopherol are
inversely associated with GC cancers, irrespective of Hp status. The
protective associations observed were similar for the cardia and
noncardia subsites, although the association for a-tocopherol may
be stronger in the diffuse histological subtype than in the intestinal
one. This study has been a comprehensive analysis of many
analytes and outcomes. Even though there is reason, based on the
antioxidant properties of carotenoids and tocopherols, and the role
of retinol in cellular growth kinetics, to believe that the findings
presented here may be real, scepticism is merited and a need exists
for the confirmation of these results in other prospective settings.
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